(Q53242492)

12 May 2018

review article

1 reference

title

Preclinical safety testing of monoclonal antibodies: the significance of species relevance. (English)

1 reference

12 May 2018

1 reference

1 reference

Kathryn Chapman

1

1 reference

12 May 2018

Nick Pullen

series ordinal

2

1 reference

12 May 2018

Mark Graham

series ordinal

3

1 reference

12 May 2018

Ian Ragan

series ordinal

4

1 reference

12 May 2018

publication date

1 February 2007

1 reference

12 May 2018

Nature Reviews Drug Discovery

published in

1 reference

12 May 2018

volume

6

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

120-126

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/nrd2242

exact match

0 references

cites work

Anti-infective monoclonal antibodies: perils and promise of development

1 reference

Monoclonal antibody successes in the clinic

31 March 2020

1 reference

Monoclonal antibodies market

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

Loss of Siglec expression on T lymphocytes during human evolution

31 March 2020

1 reference

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

31 March 2020

1 reference

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required

31 March 2020

1 reference

Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice

31 March 2020

1 reference

The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma

31 March 2020

1 reference

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

31 March 2020

1 reference

The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab

31 March 2020

1 reference

Scientific and regulatory considerations on the immunogenicity of biologics

31 March 2020

1 reference

Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals.

31 March 2020

1 reference

Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2242

1 reference

12 May 2018

1 reference

12 May 2018